罗欣药业2025年业绩预告亏损收窄，创新药商业化与研发进展受关注

Core Viewpoint - The company, Luoxin Pharmaceutical, is expected to significantly narrow its net profit loss for 2025, while its innovative drug, Tegolix, is experiencing commercial growth and key advancements in its R&D pipeline [1][2]. Financial Performance - The company forecasts a net profit loss for 2025 to be between -250 million to -340 million yuan, a substantial improvement from the -965 million yuan loss in 2024. The expected non-recurring net profit loss is projected to be between -260 million to -350 million yuan [2]. Business Development - The innovative drug Tegolix has been included in the 2025 National Medical Insurance Directory for three major indications, removing payment barriers. In the first half of 2025, the number of hospitals carrying the product surged by nearly 2,500, with sales volume increasing approximately 140% year-on-year [3]. Product R&D Progress - The injectable LX22001 is currently in Phase II clinical trials, while the Phase III clinical research report for Pucanide has been finalized and is moving towards commercialization. These advancements in innovative drugs may impact the company's long-term growth trajectory [4]. Company Status - The company completed the transfer of 100% equity in Lekang Pharmaceutical for 62.5 million yuan in January 2026 and finalized the transfer of 20% equity in Luoxin Anruo Weita in December 2025. These divestitures are expected to reduce non-operating losses, gradually alleviating future loss impacts [5]. Capital Increase - In September 2025, the company announced a plan to raise no more than 842 million yuan through a private placement, primarily for innovative drug R&D and raw material expansion projects. If implemented, this plan could optimize production capacity and support R&D investments [6]. International Expansion - As of the first half of 2025, the company has obtained over a hundred overseas registration approvals in emerging markets along the "Belt and Road" initiative, as well as in Latin America and Africa, indicating a continuous expansion of its international footprint [7]. Institutional Perspective - Zhongyou Securities initiated coverage on Luoxin Pharmaceutical in January 2026, projecting a return to revenue growth from 2025 to 2027, with a potential net profit of 320 million yuan by 2027, and assigned a "buy" rating. This external perspective may provide insights, but company announcements should be prioritized [8].